1. Toward a regulatory qualification of real-world mobility performance biomarkers in parkinson's patients using digital mobility outcomes
- Author
-
Clemens Becker, Claudia Mazzà, Walter Maetzler, Giorgio Davico, Lynn Rochester, Sabina Hernandez Penna, Judith Garcia-Aymerich, Brian Caulfield, Wilhelmus P. Dartee, Marco Viceconti, Viceconti M., Penna S.H., Dartee W., Mazza C., Caulfield B., Becker C., Maetzler W., Garcia-Aymerich J., Davico G., and Rochester L.
- Subjects
Drug trial ,Computer science ,Movement ,Wearable computer ,Walking ,lcsh:Chemical technology ,Biochemistry ,Analytical Chemistry ,03 medical and health sciences ,0302 clinical medicine ,Regulatory science ,Agency (sociology) ,Humans ,lcsh:TP1-1185 ,In patient ,030212 general & internal medicine ,Electrical and Electronic Engineering ,Instrumentation ,Scope (project management) ,Parkinson Disease ,Atomic and Molecular Physics, and Optics ,First generation ,3. Good health ,Inertial measurement unit ,Risk analysis (engineering) ,Perspective ,Algorithms ,Biomarkers ,030217 neurology & neurosurgery ,Mobility performance - Abstract
Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the first generation of these sensors was unreliable when used on slow-walking subjects. However, intense research in this area is now offering a new generation of algorithms to quantify Digital Mobility Outcomes so accurate they may be considered as biomarkers in regulatory drug trials. This perspective paper summarises the work in the Mobilise-D consortium around the regulatory qualification of the use of wearable sensors to quantify real-world mobility performance in patients affected by Parkinson’s Disease. The paper describes the qualification strategy and both the technical and clinical validation plans, which have recently received highly supportive qualification advice from the European Medicines Agency. The scope is to provide detailed guidance for the preparation of similar qualification submissions to broaden the use of real-world mobility assessment in regulatory drug trials. This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
- Published
- 2020